Extended regimens of the contraceptive vaginal ring: evaluation of clinical aspects

Contraception

Volumn 81, Issue 3, 2010, Pages 223-225

  Barreiros, Fernando Augusto ^a,b   Guazzelli, Cristina Aparecida Falbo ^a   Barbosa, Ricardo ^b   de Assis, Francisco ^b   de Araújo, Fábio Fernando ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b PAULISTA UNIVERSITY   (Brazil)

Author keywords

Clinical; Contraceptive; Ethinyl estradiol; Etonogestrel; Extended; Ring

Indexed keywords

ETHINYLESTRADIOL PLUS ETONOGESTREL;

ADULT; ARTICLE; BLOOD PRESSURE VARIABILITY; BODY MASS; BODY WEIGHT; BREAST TENDERNESS; COHORT ANALYSIS; DRUG EFFECT; DRUG RELEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; FEMALE; HEADACHE; HUMAN; IRRITABILITY; LEG PAIN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREMENSTRUAL SYNDROME; PROSPECTIVE STUDY; SIDE EFFECT; SYMPTOM; TREATMENT DURATION; VAGINA CONTRACEPTION; VAGINA RING;

ADOLESCENT; ADULT; CHI-SQUARE DISTRIBUTION; CONTRACEPTIVE DEVICES, FEMALE; DESOGESTREL; DRUG ADMINISTRATION SCHEDULE; DYSMENORRHEA; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; HEADACHE; HUMANS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 76049118961     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2009.10.007     Document Type: Article

References (12)

1. Plourd D.M., and Rayburn W.F. New contraceptive methods. J Reprod Med 48 (2003) 665-671
2. Trussell J, Vaughan B. Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999;31:64-72, 93.
3. Sulak P.J., Kuehl T.J., Ortiz M., and Shull B.L. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 186 (2002) 1142-1149
4. Miller L., Verhoeven C.H.J., and in't Hout J. Extended regimens of the contraceptive vaginal ring. Obstet Gynecol 3 (2005) 473-482
5. World Health Organization. Medical eligibility criteria for contraceptive use. 3rd ed. (2004), WHO, Geneva 112
6. Altman D. Practical statistics for medical research (1991), Chapman and Hall, London 250
7. Lewis M.A., MacRae K.D., Kuhl-Habichl D., Bruppacher R., Heinemann L.A., and Spitzer W.O. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod 14 (1999) 1493-1499
8. Fabian R. Hormonal contraception and its complications. Cesk Gynekol 52 (1987) 210-212
9. Dieben T.O., Roumen F.J., and Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 100 (2002) 585-593
10. Novák A., de la Loge C., Abetz L., and van der Meulen E.A. The combined contraceptive vaginal ring, NuvaRing®: an international study of user acceptability. Contraception 67 (2003) 187-194
11. Roumen F., Apter D., Mulders T., and Dieben T. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod 16 (2001) 469-475
12. Roumen F. Review of the combined contraceptive vaginal ring, NuvaRing. Ther Clin Risk Manag (2008) 441-451